# AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

> **NCT05191667** · PHASE1 · SUSPENDED · sponsor: **Adlai Nortye Biopharma Co., Ltd.** · enrollment: 32 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** AN0025

## Key facts

- **NCT ID:** NCT05191667
- **Lead sponsor:** Adlai Nortye Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-01-18
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 32 (ESTIMATED)
- **Why stopped:** The study is not stopped but the enrollment is suspended until a further decision from sponsor.
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05191667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05191667, "AN0025 and Chemoradiotherapy Combination in Esophageal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05191667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*